Form 4: Casdin Partners Adjusts Stake in Standard BioTools Inc. Through Cross-Trades

Casdin Partners executed a series of cross-trades involving Standard BioTools Inc. common stock, resulting in adjustments to the holdings of various Casdin-affiliated funds and entities.

Summary

• Casdin Partners Master Fund, L.P., along with affiliated entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Standard BioTools Inc. (LAB) common stock on June 18, 2024.
• The transactions involved cross-trades between different Casdin-managed funds, including Casdin Partners FO1-MSV, LP, Casdin Partners Master Fund, L.P., and Casdin Amplify Fund, LP.
• These cross-trades resulted in the transfer of 655,000 shares from Casdin Partners FO1-MSV, LP to Casdin Partners Master Fund, L.P., and 545,000 shares from Casdin Partners FO1-MSV, LP to Casdin Amplify Fund, LP, both at a price of $2.05 per share.
• Additionally, 1,200,000 shares were transferred from Casdin Partners FO1-MSV, LP to both Casdin Partners Master Fund, L.P. and Casdin Amplify Fund, LP.
• Following these transactions, Casdin Partners Master Fund, L.P. directly owns 46,730,821 shares, Casdin Amplify Fund, LP directly owns 545,000 shares, and Casdin Private Growth Equity Fund II, L.P. owns 13,939,637 shares.
• Eli Casdin directly owns 103,556 shares and indirectly owns 2,744,219 shares through Casdin Private Growth Equity Fund, L.P. and 3,774,000 shares through other means.
• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Positives

• The document does not explicitly state any positives.

Negatives

• The document does not explicitly state any negatives.

Risks

• The document does not explicitly state any risks.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders and major shareholders. This filing indicates adjustments within the Casdin Partners' investment portfolio related to Standard BioTools Inc.

Related Party Transactions

• The cross-trades between Casdin Partners FO1-MSV, LP, Casdin Partners Master Fund, L.P., and Casdin Amplify Fund, LP constitute related party transactions, as these entities are under common management by Casdin Capital, LLC and Eli Casdin.

Stakeholder Impact

• The changes in ownership may be of interest to shareholders, as they reflect the investment decisions of a major shareholder, Casdin Partners.
• The transactions themselves are unlikely to have a direct operational impact on the company's employees, customers, suppliers, or creditors.

Key Dates